Latigo laces up for $247M IPO to fund rival to Vertex's Journavx
Latigo Biotherapeutics has set terms for a $247 million IPO to fund its non-opioid pain drug rival to Vertex's Journavx.
Latigo Biotherapeutics
Private
Latigo Biotherapeutics is a clinical-stage biotechnology company developing non-opioid pain drugs that target sodium ion channels. The company recently outlined plans to go public on NASDAQ under ticker LTGO.
Company Info
Sector:Biotechnology
Headquarters:Westlake Village, California, USA
Founded:2018
Website:latigobio.com/
Funding & Investor Relations
IPO Outlook / Plans
NASDAQ IPO planned (ticker LTGO)
Upcoming Milestones & Key Dates
2026 H2
Financing
NASDAQ IPO (LTGO)
Q4 2026
Clinical
Phase 1 readout
Clinical Development Pipeline
LTGO-33
Target: Nav1.7 sodium channelUndisclosed
Target: Nav1.8 sodium channelUndisclosed
Target: TBDRecent News
Pain drugmaker Latigo outlines plans to go public
Pain drugmaker Latigo outlined plans to go public on NASDAQ under ticker LTGO.
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer